Corium (NSDQ:CORI) today announced clinical data demonstrating the strong performance of its once-daily ADHD capsule.
Boston-based Corium’s Azstarys oral capsule for treating ADHD symptoms (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]) received FDA approval in March as the first and only product containing a d-MPH oral prodrug for treating ADHD (attention deficit hyperactivity disorder) symptoms in patients aged six years and older.
Get the full story at our sister site, Drug Delivery Business News.